Turns out shareholders aren’t the only ones who have some issues with Bristol-Myers Squibb’s proposed $74 billion Celgene merger.
The Federal Trade Commission (FTC) is taking a closer look at the companies’ psoriasis drugs, both those on the market and those making their way through the clinic, Celgene said in a regulatory filing (PDF). The agency asked Bristol-Myers and Celgene Monday to hand over additional info and documents about their respective drugs.
Celgene said the companies “will continue to cooperate with the FTC staff in its review of the transactions contemplated by the Merger Agreement.”
Right now, Bristol and Celgene don’t think the review will throw off their deal timeline; they still expect the transaction to wrap in this year’s third quarter. But a potential overlap in psoriasis offerings, as determined by the FTC, could result in castoffs of marketed or pipeline products—a scenario that could hurt the combined company’s prospects as it aims to become a top immunology player.
Celgene sells Otezla, a next-generation pill that treats the skin disease. Sales have ramped up lately, with the therapy churning out $448 million in the fourth quarter to surpass last year’s haul in the same period by more than 20%. And the New Jersey drugmaker is still looking to widen Otezla’s reach: In October, it posted positive phase 3 study results in scalp psoriasis.
Bristol-Myers, meanwhile, wants to upend the market with its own psoriasis newcomer, a fellow oral option currently in phase 3. Last September, the candidate put up stellar phase 2 results, showing it could dramatically reduce symptoms in 12 weeks of treatment.
But the FTC isn’t the only force that could potentially stop the two drugmakers from joining forces. Activist investor Starboard Value has been trying to thwart the mammoth merger by rallying “no” votes from fellow shareholders—such as top stakeholder Wellington Management, which has already come out against the deal. Analysts, though, say for the time being that they still foresee the transaction going through.
By Carly Helfand
Source: Fierce Pharma
Researchers from University College London (UCL) have revealed that slow brain waves that occur during sleep could protect against increased brain excitability in patients living with epilepsy. In a study published in Nature Communications, researchers placed electrodes in 25 patients living with focal epilepsy to localise abnormal activity and inform surgical treatment.
StabiCaps gelatin formulation enhances the release of active ingredients, including medications. In May 2022, the Darling Ingredients brand also received a patent from the European Patent Office for StabiCaps for all major European countries.
In a move to participate in the race for anti-obesity drugs, Swiss pharma giant Roche has agreed to acquire Carmot Therapeutics, a privately owned US company based in Berkeley, California. Carmot’s R&D portfolio includes clinical stage subcutaneous and oral incretins with the potential to treat obesity in patients with and without diabetes, as well as a number of preclinical programs.
